ParagonDx Prepares Molecular Diagnostics Expansion After Acquisition of Gentris Diagnostics, Inc.
Published: Aug 29, 2007
MORRISVILLE, N.C.--(BUSINESS WIRE)--ParagonDx LLC, a leader in genetic and molecular testing diagnostics, has acquired the assets of Gentris Diagnostics, Inc, a subsidiary of Gentris Corporation. As a stand-alone company, ParagonDx will focus on developing molecular diagnostic products for laboratories. These products are intended to enhance medical care by providing early diagnostic information rapidly. This should benefit patients and save money for the healthcare system. Michael P. Murphy, former President and CEO of Gentris Corporation, will serve as the President and CEO of ParagonDx.